Are the Shorts Wrong About Dendreon?
In this video entry, David and Austin focus on Dendreon, which has attracted shorts as the company continues to struggle launching prostate-cancer vaccine Provenge. Is it time to invest in this cutting-edge company on the cheap, or is the high short interest a sign of further troubles ahead? Watch and find out.
Many investors are attracted to Dendreon and biotechs like it since they hold the allure of substantial short-term gains. But there's more than one approach to building long-term wealth and retiring well. In our free report "3 Stocks That Will Help You Retire Rich," we reveal some stocks that could help you as well as some winning wealth-building strategies. Click here to keep reading.
The article Are the Shorts Wrong About Dendreon? originally appeared on Fool.com.David Williamson owns shares of Johnson & Johnson and Dendreon, while Austin Smith owns shares of Johnson & Johnson, but neither holds positions in any other company mentioned. Check out Dave's holdings and a short bio. The Motley Fool owns shares of Johnson & Johnson and Dendreon. Motley Fool newsletter services have recommended buying shares of Johnson & Johnson and creating a diagonal call position in Johnson & Johnson. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.